OIPE CAR

Doc

date shown below: Signature

Typed or printed name

Marilyn Paik

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

· r.

39

TRANSMIT	TAL
FORM	

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/523,655

Filing Date February 4, 2005

First Named Inventor ESCHER, Alan P.

Art Unit To be assigned

Examiner Name To be assigned

Attorney Docket Number 14102-1US

June 13, 2005

Date

ENCLOSURES (Check all that apply)					
Fee Transmittal Form	Drawing(s)	After Allowance Communication to TC			
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences			
Amendment / Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)			
After Final	Petition to Convert to a Provisional Application	Proprietary Information			
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter			
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):			
Express Abandonment Request	Request for Refund	Statement Under 37 CFR 1.97(e) Accompanying Information Disclosure Statement; Form			
Information Disclosure Statement CD, Number of CD(s)		PTO/SB/08a/B, copies of 4 references & Postcard			
Certified Copy of Priority	Landscape Table on CD				
Document(s)	Remarks				
Response to Missing Parts/ Incomplete Application	Also, enclosed is copy of Supplementary Partial European Search Report issued by the EPO in corresponding application.				
Reply to Missing Parts under					
37 CFR 1.52 or 1.53					
	<u> </u>				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name SHELDON & MAK PC					
Signature Darl Faral					
Printed name David A. Farah, M.D.					
Date June 13, 2005	Reg. No	. 38,134			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING Docket No. 14102-1US 4ATION DISCLOSURE STATEMENT ESCHER, Alan P. et al. In Re Application Of: JUL 1 8 2005 **Application** na Date Examiner Customer No. Group Art Unit Confirmation No. February 4, 2005 23676 To be assigned 10/523,655 To be assigned To be assigned SUBSTANCES FOR PREVENTING AND TREATING AUTOIMMUNE DISEASES Invention: **COMMISSIONER FOR PATENTS:** This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application. Check applicable statement herebelow: Statement Under 37 CFR 1.97(e)(1) ☐ Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement. Statement Under 37 CFR 1.97(e)(2) No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement. Dated: June 13, 2005 Reg. No. 38,134 David A. Farah, M.D. SHELDON & MAK PC Certificate of Mailing by First Class Mail 225 South Lake Avenue, Suite 900 I certify that this correspondence is being deposited with Pasadena, California 91101

Tel.: (626) 796-4000 Fax: (626) 795-6321 eMail: davidf@usip.com

cc: Loma Linda University

the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

June 13, 2005

(Date)

Signature of Per Mailing Correspondence

Marilyn Paik

Typed or Printed Name of Person Mailing Correspondence

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2

Sheet of

Complete if Known				
Application Number	10/523,655			
Filing Date	February 4, 2005			
First Named Inventor	ESCHER, Alan P.			
Art Unit	To be assigned			
Examiner Name	To be assigned .			
Attorney Docket Number	14102-1US			

U.S. PATENT DOCUMENTS						
Examiner Cite Initials* No.1		Document Number Number Kind Code		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
indas	110.	US-	Kind Code (if known)	11111-00-1111		r igaios rapoui
		US-				
		US-	ļ			
		US-				
		US-				
		US-				•
		US-				
		US-			•	
		US-				
		US-				
		US-				
		US-		-		1.000
		US-				,
		US-		. "		
		US-				
		US-	i			
		US-	İ			
		US-				
		US-				·
		US-		·		

	FOREIGN PATENT DOCUMENTS							
Examiner Cite	Foreign Patent Document Office ³ Number ⁴ Kind ⁵			Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant		
Initials*	No.1	Office ³	Number ⁴	(if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶
	Al	US	WO 00/59538	A	10-12-2000	The John Hopkins Univ.		
<u> </u>		<u> </u>						₩
		ļ				ļ		1_
	<u> </u>						ļ	┼
	ļ							+
							· · · · · · · · · · · · · · · · · · ·	+
		\vdash						+

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number 10/523,655

Filing Date February 4, 2005

First Named Inventor ESCHER, Alan P.

Art Unit To be assigned

Examiner Name To be assigned

Sheet of Attorney Docket Number 14102-1US OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials No.1 publisher, city and/or country where published. FILIPOVA M. ET AL: "Effects of Plasmid DNA Injection on Cyclophosphamide-Accelerated Diabetes in NOD Mide," DNA and Cell Biology, New York, NY, US, Vol. 20, No. 3, March 1, 2001, pp. 175-181 ВI LI A. F. ET AL: "Co-Delivery of Pro-Apoptotic BAX With a DNA Vaccine Recruits Dendritic Cells and Promotes Efficacy of Autoimmune Diabetes Prevention in Mice," Vaccine, Butterworth Scientific B2 Guildford, GB, Vol. 22, No. 13-14, April 16, 2004, pp. 1751-1763 TOKUI M. ET AL: "Studies on the Prevention of Diabetes in NOD Mice by Intramuscular Administration of Plasmic Expressing GAD and IL-4," Chemical Abstracts + Indexes, American Chemical Society, Columbus, OH, US, Vol. 25, No. 125, 1996, p. 1148 **B3**

Examiner		Date	
Signature	·	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.